Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT03937219. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.
Study identification
- NCT ID
- NCT03937219
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 855 participants
Conditions and interventions
Conditions
Interventions
- Cabozantinib Drug
- Nivolumab Biological
- Ipilimumab Biological
- Cabozantinib-matched placebo Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 25, 2019 (Actual)
- Primary completion
- Jan 31, 2022 (Actual)
- Completion
- Jan 31, 2027 (Estimated)
- Last update posted
- Oct 20, 2026
2019 – 2027
United States locations
- U.S. sites
- 30
- U.S. states
- 19
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #116 | La Jolla | California | 92093 | — |
| Exelixis Clinical Site #166 | Orange | California | 92868-3201 | — |
| Exelixis Clinical Site #29 | Boca Raton | Florida | 33486 | — |
| Exelixis Clinical Site #44 | Miami | Florida | 33176 | — |
| Exelixis Clinical Site #3 | Atlanta | Georgia | 30318 | — |
| Exelixis Clinical Site #95 | Chicago | Illinois | 60612 | — |
| Exelixis Clinical Site #69 | Scarborough | Maine | 04074 | — |
| Exelixis Clinical Site #58A | Baltimore | Maryland | 21287 | — |
| Exelixis Clinical Site #7B | Boston | Massachusetts | 02114 | — |
| Exelixis Clinical Site #7A | Boston | Massachusetts | 02215 | — |
| Exelixis Clinical Site #7C | Boston | Massachusetts | 02215 | — |
| Exelixis Clinical Site #6 | Burlington | Massachusetts | 01805 | — |
| Exelixis Clinical Site #15 | Detroit | Michigan | 48201 | — |
| Exelixis Clinical Site #24 | Kansas City | Missouri | 64132 | — |
| Exelixis Clinical Site #4 | St Louis | Missouri | 63110 | — |
| Exelixis Clinical Site #2 | Omaha | Nebraska | 68130 | — |
| Exelixis Clinical Site #159 | New York | New York | 10032 | — |
| Exelixis Clinical Site #8 | New York | New York | 10065 | — |
| Exelixis Clinical Site #19 | Syracuse | New York | 13210 | — |
| Exelixis Clinical Site #101 | Charlotte | North Carolina | 28204 | — |
| Exelixis Clinical Site #107 | Portland | Oregon | 97239 | — |
| Exelixis Clinical Site #12 | Pittsburgh | Pennsylvania | 15232 | — |
| Exelixis Clinical Site #102 | Charleston | South Carolina | 29425 | — |
| Exelixis Clinical Site #5 | Myrtle Beach | South Carolina | 29572 | — |
| Exelixis Clinical Site #10 | Nashville | Tennessee | 37203 | — |
| Exelixis Clinical Site #38 | Nashville | Tennessee | 37232 | — |
| Exelixis Clinical Site #64 | Fairfax | Virginia | 22031 | — |
| Exelixis Clinical Site #57 | Seattle | Washington | 98109 | — |
| Exelixis Clinical Site #1 | Spokane | Washington | 99208 | — |
| Exelixis Clinical Site #13 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 129 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03937219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03937219 live on ClinicalTrials.gov.